GlobeNewswire by notified

Cellebrite Enterprise Solutions 2023 Industry Trends Report Finds 70 Percent of eDiscovery Professionals State Accessing Data Offsite Is a Major Endpoint Collection Problem

Share

Hybrid work causing major data collection headaches for eDiscovery professionals, slowing down corporate fraud, IP theft and sexual assault investigations

Collecting data from offsite mobile devices, chat apps and remote employees are some of the top challenges faced by corporate investigators

PETAH TIKVA, Israel and TYSONS CORNER, Va., Jan. 24, 2023 (GLOBE NEWSWIRE) -- A study commissioned by digital intelligence leader Cellebrite DI Ltd. (NASDAQ: CLBT) has revealed that hybrid work is creating major data collection headaches for eDiscovery professionals and corporate investigators and is slowing down corporate fraud, IP theft and sexual harassment investigations.

The data reveals that both in-house and agency investigators are facing new challenges caused by the pandemic-induced rise in hybrid and remote working. The top three issues highlighted by respondents are as follows:

  • 70 percent of eDiscovery professionals say accessing data from offsite mobile devices is a major endpoint collection problem
  • 63 percent of eDiscovery professional say accessing data from WhatsApp, WeChat and Telegram is a major endpoint collection problem
  • 56 percent of eDiscovery professionals say collecting data from employees working remotely is a major endpoint collection problem

The data, gathered from 550 eDiscovery professionals and corporate investigators in 45 countries, also illustrates how the abundance of chat and collaboration tools – again accelerated by the pandemic – is spreading digital evidence across a broadening range of platforms.

Cellebrite Enterprise Solutions’ Endpoint Inspector helps relieve these pain points by:

  • Creating and defining targeted collections from remote computers, remote mobile devices, and supported cloud workplace applications like Office365, Google Workspace, Slack and Box
  • Easily collecting only what is needed from endpoints and cloud workplace applications without employees having to hand over their device, saving valuable resources
  • Accessing a single source for cloud workplace app collection without logging into every app and pulling all data from multiple sources for every employee

Ken Basore, General Manager at Cellebrite Enterprise Solutions comments:“This study clearly shows that the rise in hybrid working is creating new challenges for investigators such as remote data extraction and the splintering of data across emerging collaboration tools. Organizations must equip professionals with the people, skills and technology required to extract, analyze, manage and store remote digital evidence. If these investments aren’t made, there will be real world consequences including rising cases of business fraud, growing, exposure to civil litigation, possible adverse judgments, unrecoverable financial losses and victims of workplace crimes that do not get the justice they need.”

Joe Pochron, Digital Forensics & Insider Threat Lead, Forensic & Integrity Services Ernst & Young LLP: “As you can see from Cellebrite’s Industry Trends survey, remote collection is growing more and more important for eDiscovery professionals. The growing landscape of collaboration tools provides a deluge of information to investigate. Thankfully, Cellebrite Enterprise Solutions provides the tools necessary to zone in on the data needed for corporate examinations.”

The report, which can be downloaded here, contains a wealth of data about the different ways corporate investigators and third-party service providers are using digital evidence. It contains actionable recommendations for organizations looking to enhance their remote collection capabilities and management of digital artefacts.

About Cellebrite
Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more, visit us at www.cellebrite.com.

About Cellebrite Enterprise Solutions

In a world that’s evolving rapidly, Cellebrite Enterprise Solutions looks beyond the horizon to design solutions to keep data within reach, transform it, and reveal important insights to protect your business and employees. From headquarters to home office, eDiscovery professionals and corporate investigators can access endpoints anywhere with Cellebrite’s enterprise solution offerings.

Media

Victor Cooper
Public Relations and Corporate Communications Director
+1 404 804 5910
victor.cooper@cellebrite.com

Investors

Investor Relations

investors@cellebrite.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update8.5.2024 22:15:38 CEST | Press release

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDACBased on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the first quarter and provided a business update. “At the upcoming 2024 ASCO meeting, we are looking forward to presenting multiple datasets including the first clinical data on safety and efficacy of petosemtamab in combination with pembrolizumab in previously untreated head and neck cancer. With p

CrossAmerica Partners LP Reports First Quarter 2024 Results8.5.2024 22:15:00 CEST | Press release

Allentown, PA, May 08, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Reports First Quarter 2024 Results Reported First Quarter 2024 Net Loss of $17.5 million that includes a $15.9 million loss on lease terminations with Applegreen, Adjusted EBITDA of $23.6 million and Distributable Cash Flow of $11.7 million compared to a Net Loss of $1.0 million, Adjusted EBITDA of $31.7 million and Distributable Cash Flow of $19.1 million for the First Quarter 2023Reported First Quarter 2024 Gross Profit for the Wholesale Segment of $27.0 million compared to $31.2 million of Gross Profit for the First Quarter 2023 and First Quarter 2024 Gross Profit for the Retail Segment of $54.4 million compared to $50.8 million of Gross Profit for the First Quarter 2023Leverage, as defined in the CAPL Credit Facility, was 4.49 times as of March 31, 2024, compared to 4.21 times as of December 31, 2023The Distribution Coverage Ratio for the trailing twelve months ended March 31, 2024 was 1.37 times compared to 1

Oculis Reports Q1 2024 Financial Results and Provides Company Updates8.5.2024 22:10:00 CEST | Press release

ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive leadership team and U.S. presence with the appointments of accomplished and seasoned professionals as President of Research & Development and Chief Human Resources Officer Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the three-month period ended March 31, 2024, and an overview of the Company’s progress. Riad Sherif M.D., Chief

Nokia Corporation: Repurchase of own shares on 08.05.20248.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 08 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 08.05.2024 Espoo, Finland – On 08 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL362,9483.49CEUX--BATE--AQEU--TQEX--Total362,9483.49 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Trading in GN Store Nord shares by board members, executives and associated persons8.5.2024 21:28:31 CEST | Press release

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated Name Jørgen Bundgaard Hansen Reason for the notification Position/status Member of the Board of Directors Initial notification/Amendment Initial notification Details of the issuer Name GN Store Nord A/S LEI 5493008U3H3W0NKPFL10 Details of the transaction(s) Description of the financial instrument, type of instrument Identification code Shares DK0010272632 Nature of the transaction Purchase of shares Price(s) and volume(s) Price(s) DKK 201.0 DKK 201.1 DKK 201.1 DKK 201.0 DKK 201.0 DKK 201.0 DKK 201.1 DKK 201.1 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.0 DKK 201.3 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.2 DKK 201.3 DKK 201.5 DKK

HiddenA line styled icon from Orion Icon Library.Eye